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Abstract. The Deployment and Travel Medicine Knowledge, Attitudes, Practices, and Outcomes Study (KAPOS)
examines the integrated relationship between provider and patient inputs and health outcomes associated with travel and
deployments. This study describes malaria chemoprophylaxis prescribing patterns by medical providers within the U.S.
Department of Defense’s Military Health System and its network of civilian healthcare providers during a 5-year period.
Chemoprophylaxis varied by practice setting, beneﬁciary status, and providers’ travel medicine expertise. Whereas both
civilian and military facilities prescribe an increasing proportion of atovaquone–proguanil, doxycycline remains the most
prevalent antimalarial at military facility based practices. Civilian providers dispense higher rates of meﬂoquine than their
military counterparts. Within military treatment facilities, travel medicine specialists vary their prescribing pattern based on
service member versus beneﬁciary status of the patient, both in regards to primary prophylaxis, and use of presumptive
anti-relapse therapy (PQ-PART). By contrast, nonspecialists appear to carry over practice patterns developed under force
health protection (FHP) policy for service members, into the care of beneﬁciaries, particularly in high rates of prescribing
doxycycline and PQ-PART compared with both military travel medicine specialists and civilian comparators. Force health
protection policy plays an important role in standardizing and improving the quality of care for deployed service members,
but this may not be the perfect solution outside of the deployment context. Solutions that broaden both utilization of
decision support tools and travel medicine specialty care are necessary.

conundrum that variation in practice may reﬂect not only on a
wide range of clinically acceptable practices with attendant
potential ﬁscal inefﬁciencies but also medical errors that impact
quality and patient outcomes.15,16 The current study analyzes
data from 2012 to 2016, a time period encompassing both
troop-level decline in Afghanistan, where doxycycline was the
ﬁrst-line prophylactic agent against malaria, and the Ebola virus
disease outbreak in West Africa, leading to a large-scale deployment of troops, for whom atovaquone–proguanil was the
FHP policy ﬁrst-line prophylactic.17 This study affords the opportunity to assess antimalarial prescription pattern changes
over time, as well as variability in practice patterns as a function
of practice setting and practice of travel medicine as a specialty.

INTRODUCTION
The U.S. military identiﬁes malaria as among the most important infectious disease threat to the health and operational
readiness of deployed forces.1 Annual case burden within the
U.S. military varies based on the geographic and operational
posture of the force, ranging from 35 to 126 in between the time
period of 2009−2018.2 The U.S. military uses a detailed set of
force health protection (FHP) policies and procedures encompassing a broad array of medical threats, to include malaria.3–6
Unfortunately, sporadic outbreaks of malaria remain an ongoing
concern to the military leading to heightened emphasis by
commanders and medical leadership makers on the use of FHP
policies.7,8 These policies, when effectively monitored by
commands, have been proven to dramatically reduce the risk of
malaria during deployments.9–11 Malaria is also a signiﬁcant
medical concern to the broader beneﬁciary population of the
Military Health System as well as those service members traveling to malaria-endemic regions while on leave.12,13 A previous
study, conducted after a major FHP policy shift in 2009, away
from the use of meﬂoquine as a ﬁrst-line antimalarial agent,
demonstrated that patterns prescribed by the Military Health
System for antimalarial medications varied both as a function of
the medical specialty of the ordering provider and time.14 Results from this study led to the question of whether this variation
results from whether a provider is able to individualize their
medical practice based on the needs of the patient or whether
they reﬂexively apply policies intended for active duty military
deployments to non-active duty beneﬁciaries (e.g., family
members and retirees). A body of literature, including several
reports by the National Academy of Sciences, point to the

METHODS
This analysis represents a line of inquiry within the Deployment and Travel Medicine Knowledge, Attitudes, Practices, and Outcomes Study (KAPOS). KAPOS examines the
integrated relationship between provider and patient inputs
and health outcomes associated with travel and deployments.
This research was approved by the Uniformed Services University of the Health Sciences Institutional Review Board.
The Military Health System provides comprehensive medical care to 9.5 million beneﬁciaries, worldwide, through a
network of 51 military hospitals, 424 military health clinics, and
a national and international network of participating civilian
TRICARE medical providers.18 This includes 1.4 million active
duty service members, 1.7 million active duty family members,
0.8 million service members on reserve status and their families, and 5.4 million retired military and their families. The
Military Health System uses an electronic medical record that
sends administrative and clinical data points into an integrated administrative record system called the Military Health
System Data Repository (MDR). Used to analyze health care
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data from both military and civilian medical facilities, pharmacies, and medical providers worldwide, the MDR also collects claims data on Military Health System beneﬁciaries from
the civilian sites. This encompasses more than 70 million annual outpatient visits, one million hospital admissions, and 128
million prescriptions annually.18 The MDR and its various
component data ﬁles, such as the Pharmacy Data Transaction
Service, serve as the foundational data set for the clinical
practice trends described in this article
All antimalarial medications prescribed from ﬁscal years
(October through September) 2012–2016, for all patients receiving care funded by the Military Health System, regardless
of location or duty status were identiﬁed. This analysis presents data on individuals aged 18 years and older. Individual
medication prescriptions were identiﬁed with the following
associated variables: patient age, gender, sponsor branch of
service, year of prescription, beneﬁciary status of the patient,
amount dispensed, number of reﬁlls, dispensing facility and
type (e.g., civilian versus military), and the prescriber’s medical
expenses and performance reporting system (MEPRS) code.
The MEPRS code allows for the designation of medical specialty of the prescribing clinic from military facilities. Prescriptions from military facilities lacking an MEPRS code were
excluded from provider specialty-based analyses. Both patients and medical providers were assigned unique study
identiﬁcation numbers for comparative analyses.
Outpatient medication prescription records for malaria
chemoprophylaxis were included in the study based on
the following working deﬁnitions and inclusion criteria for
atovaquone–proguanil (AP), meﬂoquine (MQ), chloroquine
(CQ), doxycycline (DX), and primaquine (PQ). Primaquine was
further characterized as primary prophylaxis (PQ-1) and presumptive anti-relapse therapy (PQ-PART), which was analyzed separately. All AP and MQ prescriptions were included.
Doxycycline was ﬁltered out of the initial search if codispensed with either isotretinoin or topical medications
typically used in the treatment of acne or rosacea, using the
American Hospital Formulary Service drug class, as were the
prescriptions associated with dermatology MEPRS codes.
Doxycycline was further censored to include only those
dispensed as one tablet daily, and those with twice-daily
(therapeutic) dosing schemes were excluded. Doxycycline
prescriptions of 100-mg tablets with a days supply of 36 or
more days, representing the minimum number of tablets
dispensed using CDC guidelines for 1 week of travel to a
malaria-endemic region were included. Chloroquine prescriptions associated with rheumatology clinics were excluded
because of potential indexing issues with hydroxychloroquine.
Prescriptions of PQ were sorted by quantity as a proxy for indication. Primaquine in amounts less than eight tablets were
excluded from the analysis. Primaquine tablet quantities of 14,
28, and 30 were designated as PQ-PART. Primaquine in other
amounts were designated PQ-1. Artemether–lumefantrine and
quinine prescriptions were not included in the analysis. Reﬁlls
were counted as a single, index prescription.
Data analyses were performed on SAS version 9.4 software
(SAS Institute Inc., Cary, NC). Descriptive statistics were generated for all variables using Pearson’s chi-square test for categorical variables. These results were then stratiﬁed by facility
status and by military or beneﬁciary status. Facility status included military treatment facilities (MTFs) as deﬁned by prescriptions ﬁlled at either military hospitals and clinics, or deployed

FIGURE 1. Malaria primary chemoprophylaxis prescriptions included in the analysis.

medical units, and civilian facilities as deﬁned by prescriptions
from nonmilitary medical facilities, retail pharmacies, and mail
order prescriptions. Study subjects were identiﬁed as “service
member” if identiﬁed by codes for active duty personnel, National
Guard and Reserve personnel, or “beneﬁciary” which would
principally include military retirees and their dependents, as well
as the dependents of service members. Individuals with unknown beneﬁciary status were removed before analysis.
Proportions of prescribed medications were categorized
based on both military service status and, for MTFs, the prescribing provider’s clinic’s travel medicine expertise designation.
Within the Military Health System, infectious disease (adult and
pediatric), preventive medicine, and allergy–immunology clinics
typically provide dedicated travel medicine services, and for analytic purposes, “Travel Medicine Specialist” clinics were considered. Pareto charts were developed to determine the
proportion of chemoprophylaxis-prescribed travel medicine specialists and aggregated by either unique providers or by unique
facilities. Odds ratios, with 95% CIs, were calculated to determine
the magnitude of difference in malarial chemoprophylaxis medication prescriptions by facilities and travel medicine specialist by
either service member or beneﬁciary status. Civilian facility prescriptions were used as the control comparison group between
facilities and between specialist categories for comparison by
medications. Odds ratio results were then plotted into a forest plot.
RESULTS
Chemoprophylaxis prescriptions were included for analysis as described in Figure 1. A total of 432,920 unique adult
study subjects (Table 1) were prescribed 586,672 malaria
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TABLE 1
Patient demographic characteristics by beneﬁciary category and by facility type
Military treatment facilities (N = 396,911)

Age-group (years)
18–49
50–64
> 64
Gender
Male
Female
Sponsor service*
Army
Air Force
Navy/Marine Corps
Other

Service members
(col %) (N = 359,587)

Beneﬁciaries (col %)
(N = 37,324)

352,761 (98.1)
6,615 (1.8)
211 (< 1)

Civilian facilities (N = 36,009)
P-value

Service members
(col %) (N = 6,555)

Beneﬁciaries
(col %) (N = 29,454)

P-value

18,676 (50.0)
11,655 (31.2)
6,993 (18.7)

< 0.0001
–
–

6,120 (93.4)
433 (6.6)
2 (< 1)

9,296 (32.0)
8,284 (28.0)
11,774 (40.0)

< 0.0001
–
–

316,600 (88.0)
42,987 (12.0)

19,255 (51.6)
18,069 (48.4)

< 0.0001
–

5,297 (80.8)
1,258 (19.2)

12,749 (43.3)
16,705 (56.7)

< 0.0001
–

243,190 (68.0)
72,363 (20.2)
39,807 (11.0)
2,058 (< 1)

–
–
–
–

–
–
–
–

3,495 (53.2)
1,524 (23.3)
1,075 (16.4)
461 (7.0)

–
–
–
–

–
–
–
–

* A total of 2,650 individuals did not have a sponsoring military service identiﬁed.

chemoprophylaxis prescriptions for DX (74%), AP (22%), MQ
(2%), CQ (1%), and PQ-1 (< 1%) during the study period from
ﬁscal years 2012–2016 across both military and civilian
medical facilities. Seventy-eight percent of study subjects
(n = 340,657) were prescribed only one prescription for the
study period. The remaining 92,263 unique individuals were
prescribed more than one chemoprophylaxis with the median and interquartile range of 2 (2–3) prescriptions. The
majority of prescriptions were prescribed by MTFs (89%)
compared with civilian facilities (11%). Overall patient demographics consist of a majority of whom are younger than
50 years (90%) and male (82%). Military facilities have a high
proportion of active duty–aged males and a relatively

younger pool of beneﬁciaries, reﬂecting spouses and children of service members, compared with civilian facilities
represented by smaller proportion of service members and
an older population of beneﬁciaries. The Army is the most
common military sponsor branch of service (68%), followed
by Air Force (20%), and Navy/Marine Corps (11%). Other
branches of the Uniformed Services that receive care in the
Military Health System include Coast Guard, Commissioned
Corps of the Public Health Service, and the National Oceanographic and Atmospheric Administration.
Aggregate adult annual chemoprophylaxis patterns from
military facilities for all ﬁve ﬁscal years are shown in Figure 2A.
The overall decrease in total chemoprophylaxis prescriptions

FIGURE 2. (A) Annual adult chemoprophylaxis patterns from military facilities. (B) Annual adult chemoprophylaxis patterns from civilian facilities.
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through the years correlates with military troop levels deployed
to Afghanistan during that time period. Atovaquone–proguanil
volume increases from 7.2% of total annual prescriptions in
2012–37% by 2016 and DX use shows a proportional decline
from 89% to 62% during the study period. Meﬂoquine use
declines from 2.2% of prescriptions to 0.6% by 2016. Trend
changes for each antimalarial medication by ﬁscal year are
statistically signiﬁcant with P-value < 0.0001. Aggregate adult
annual chemoprophylaxis patterns by civilian facility for all ﬁve
ﬁscal years are shown in Figure 2B. Trend changes for each
antimalarial medication by ﬁscal year are statistically signiﬁcant
with P-value < 0.0001 except PQ-1 (P-value: 0.786).
Comparative prescribing trends at military facilities are
shown for service members (Figure 3A) versus beneﬁciaries
(Figure 3B). Among service members, use of AP shows a
steady upward trend with peak usage in ﬁscal year 2015. As
aforementioned, DX use declines in both absolute and percent
of the total but remains the majority choice for prophylaxis.
Meﬂoquine use, already uncommon in 2012 (1%), shows a 15fold reduction in absolute prescriptions and accounts for < 1%
in 2016. Among non-service members, AP use shows a similar
upward trajectory in use over time expanding from 20% to
38% of the total as DX use declines in absolute and proportional terms from 70% to 58% and MQ use at MTFs among
beneﬁciaries also shows steady decline in usage within the
study period, but remains relatively more common from 6.5%
in 2012 to 2.0% in 2016.
Prescriptions from civilian sites for service members
(Figure 3C) and beneﬁciaries (Figure 3D) show lower reliance
on DX in both populations, with AP as the most commonly
prescribed medication for both groups by 2016. Meﬂoquine
use, although still in the minority, is more commonly prescribed by civilians to service members (11% in 2012–5% in
2016) and beneﬁciaries (14% in 2012–6% in 2016) than by
military facility providers.
Military facility prescriptions were also coded by clinic
specialty type allowing comparison of the proportion of prophylaxis prescription by various provider specialties. Prescriptions by MTFs without MEPRS codes numbered (n =
159,187 [31%]) were not included in the provider specialist
analysis results. Given that 75% of these prescriptions are for
doxycycline and 88% were prescribed to service members,
these most likely represent prescriptions dispensed centrally
by base pharmacies for deploying units. The highest volume of
malarial chemoprophylaxis occurs at general primary care
clinics, which are often oriented to serve the needs of active
duty service members and would typically represent a mix of
primary care medical specialties as well as nurse practitioners
or physician assistants. In many cases, these may also be
free-standing deployment mobilization clinics. A total of
198,544 prescriptions which accounts for about 62% of
the total prescribed to service members at MTFs came from
these clinics.
Odds ratios were calculated for each prophylactic medication between both service members and beneﬁciaries at
military facilities, using civilian facilities as the control
(Figure 4A, and Tables 2 and 3). The odds of prescribing DX to
a service member at a military facility is higher than prescribing
to a non-service member beneﬁciary (service members: 4.86,
95% CI: 4.70–5.05; beneﬁciary: 2.76, 95% CI: 2.70–2.83).
Similarly, AP, CQ, and MQ all have decreased odds of being
prescribed at military facilities to both service members and
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beneﬁciaries. By contrast, the total volume is low in absolute
terms, PQ-1 has higher odds of prescribing at MTFs to beneﬁciaries (1.92, 95% CI: 1.54–2.40) but decreased odds of
prescribing PQ-1 at MTFs to service members (0.60, 95% CI:
0.42–0.85). Among service members, PQ-PART was prescribed to 45.3% at MTFs compared with 9.4% at civilian
facilities.
Figure 4B and Table 4 represent prescribing patterns at
MTFs by travel medicine specialists compared with civilian
providers as the control. Compared with civilian providers, the
odds of prescribing AP by a military travel medicine specialist
are higher both for beneﬁciaries (4.30, 95% CI: 4.06–4.54) and
service members (1.14, 95% CI: 1.08–1.20). For service
members, DX is prescribed at higher odds (1.26 95% CI:
1.19–1.33) than beneﬁciaries (0.28, 95% CI: 0.25–0.30). Travel
medicine specialists at MTFs were more likely to prescribe
PART to both service members (OR: 1.47) and beneﬁciaries
(OR: 8.68) compared with the civilian providers.
Figure 4C, Table 5 represent the prescribing patterns by
non-travel medicine specialists at MTFs to service members
and dependent/retirees, with civilian providers as the control.
The odds of prescribing AP by a nonspecialist is lower for both
beneﬁciaries (0.36, 95% CI: 0.35–0.38) and service members
(0.27, 95% CI: 0.26–0.28). Military nonspecialists prescribe DX
to both service members and beneﬁciaries at higher odds
(service members: 5.62, 95% CI: 5.41–5.83; dependents/
retirees: 4.12, 95% CI: 4.01–4.24) than civilian comparators
but are less likely to prescribe MQ to service members (OR:
0.12) or beneﬁciaries (OR: 0.40). Military nonspecialists prescribe PART at signiﬁcantly higher rates than civilian providers
for both service members (OR: 7.42) and particularly beneﬁciaries (OR: 53.4).
A total of 14,625 unique nonspecialist providers prescribed
a total of 465,357 primary prophylaxis prescriptions during the
study period. The volume per provider ranges from a single
provider with 6,880 prescriptions, to 4,285 providers with only
a single prescription. The median number of prescriptions was
3 (IQR: 1–11). Eighty percent of nonspecialists (n = 11,743)
wrote 10 or fewer malaria chemoprophylaxis prescriptions
during the 5-year study period.
Facility-level analysis demonstrated a total of 163 unique
facilities with travel medicine specialists prescribing 16,202
malarial chemoprophylaxis prescriptions (Supplementary
Figure 5A). The facility with the highest number of prescriptions for the study period is from Walter Reed National Military
Medical Center (WRNMMC, N = 2,439), which represents 15%
of the total number of prescriptions by specialty clinics. Eighteen facilities represent the top 80% of the total antimalarial
prescriptions among travel medicine specialists. By contrast,
339 unique facilities (Supplementary Figure 5B) were identiﬁed
to have nonspecialists prescribing 345,573 malarial chemoprophylaxis prescriptions. The facility with the highest number
of prescriptions are from Fort Bragg, N = 22,557, which represents about 7% of the total number of prescriptions by nonspecialty clinics. A total of 51 facilities represent the top 80% of
the total antimalarial prescriptions by non-travel medicine
specialists.
DISCUSSION
From its earliest use among allied forces in the Paciﬁc
Campaign of World War II, malaria chemoprophylaxis has
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FIGURE 3. (A) Annual adult chemoprophylaxis patterns at military treatment facilities (MTFs) prescribed to service members by ﬁscal years. (B)
Annual adult chemoprophylaxis patterns at MTFs prescribed to beneﬁciaries by ﬁscal years. (C) Annual adult chemoprophylaxis patterns at civilian
facilities prescribed to service members by ﬁscal years. (D) Annual adult chemoprophylaxis patterns at civilian facilities prescribed to beneﬁciaries
by ﬁscal years.

been a priority for the U.S. military, leading to the dictum that
ensuring adherence is not just a medical responsibility, but a
command responsibility.19 Recent experience with U.S. military operations in sub-Saharan Africa and Afghanistan have

shown ongoing problems with low adherence to doxycycline
and meﬂoquine chemoprophylaxis, often leading to outbreaks
of malaria.7,8,20 One notable exception to this experience is the
very high rate of reported adherence and lack of cases

MALARIA CHEMOPROPHYLAXIS IN THE MILITARY HEALTH SYSTEM
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FIGURE 4. (A) Comparison of prescriptions by military vs. civilian facility providers. (B) Comparison of prescriptions by military travel medicine
specialists vs. civilian providers. (C) Comparison of prescriptions by military travel medicine nonspecialists vs. civilian facility providers.

reported among U.S. military forces while deployed to Liberia
as part of the Ebola virus outbreak response Operation United
Assistance in 2014–2015.10 Faced with a well-known, high
threat from infectious diseases in this operation, the military
health community provided robust, expert-level consultation

on FHP measures to all deploying forces and consistently
reinforced them in an ongoing manner during the deployment
to a level not seen in previous deployments.17 This suggests
that how risk management and prevention information is
provided and, by whom, may have greater impact on
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TABLE 2
Comparison of MTF vs. civilian facility prescription to service
members
Medication

Atovaquone—
proguanil
Chloroquine
Doxycycline
Meﬂoquine
Primaquine
Total
Presumptive antirelapse therapy

MTF, N (%)

Civilian, N (%)

OR (95% CI)

83,668 (18.2)

4,970 (42.0)

0.30 (0.29–0.31)

2,346 (0.5)
367,465 (80.1)
4,726 (1.0)
805 (0.2)
459,010
380,298 (82.8)

645 (5.5)
5,301 (45.4)
779 (6.6)
34 (0.2)
11,729
1,224 (10.4)

0.09 (0.08–0.10)
4.86 (4.70–5.05)
0.15 (0.14–0.16)
0.60 (0.42–0.85)
–
7.94 (7.48–8.42)

TABLE 4
Comparison of MTF specialists vs. civilian facility prescriptions
Medication

Atovaquone–proguanil
Chloroquine
Doxycycline
Meﬂoquine
Primaquine
Presumptive anti-relapse
therapy

Service member, OR
(95% CI)

1.14 (1.08–1.20)
0.17 (0.14–0.22)
1.26 (1.19–1.33)
0.30 (0.26–0.36)
0.86 (0.50–1.48)*
1.47 (1.36–1.60)

Beneﬁciaries, OR (95%
CI)

4.30 (4.06–4.54)
0.26 (0.22–0.30)
0.28 (0.25–0.30)
0.60 (0.54–0.65)
1.83 (1.23–2.72)
8.68 (7.38–10.20)

* No statistically signiﬁcant results.

MTF = military treatment facility.

knowledge, attitudes, and practices of deployers/travelers
than merely what information is provided or what is
prescribed.21,22
Within the Military Health System, antimalarial prescriptions
are driven largely by the deployment of active duty service
members and the FHP policies that determine medication
selection. Reﬂecting the operational tempo, scale, and location of a globally deployed force, the prescription patterns
during this study’s time period reﬂect force reductions over
time in Afghanistan (where DX is the ﬁrst-line agent) as well as
increased operations in sub-Saharan Africa (notably for the
Ebola outbreak in 2014 and 2015), where AP is the ﬁrst-line
agent. Particularly noteworthy is the sustained sharp reductions in MQ use by military health providers, particularly
among the service members, over the past decade in response to emerging concerns about neuropsychiatric side
effects and changes in the FHP policy.14 Aggregate prescriptions from civilian providers consistently reﬂect higher
rates of MQ, CQ, and AP use. Although absolute numbers are
small (well below 1% of the total number of prescriptions),
military providers were more likely to use PQ-1 for beneﬁciaries than their civilian counterparts. This may reﬂect unique
aspects of the population (including destination of travel),
more detailed knowledge about travel medicine, or more
generalizable prior experience with PQ as PART.
When military facility data are parsed, specialties in which
travel medicine services constitute a core component of
graduate medical education and routine practice, are much
more likely to use AP then their generalist counterparts, particularly when caring for beneﬁciaries, that is, they make
context-speciﬁc shifts in practice. Although all military facility
medical providers have access to on-line resources (e.g., the
CDC’s yellow book and Shoreland’s Travax), utilization rates
are unknown, and these resources are generally neutral about
ranking a preferred chemoprophylaxis agent. Rather, the
TABLE 3
Comparison of MTF vs. civilian facility prescription to beneﬁciaries
Medication

MTF, N (%)

Civilian, N (%)

Atovaquone–
18,665 (30.1) 23,109 (42.8)
proguanil
Chloroquine
1,298 (2.1)
4,614 (8.6)
Doxycycline
39,002 (62.9) 20,536 (38.0)
Meﬂoquine
2,727 (4.4)
5,604 (10.4)
Primaquine
260 (0.4)
118 (0.2)
Total
61,952
53,981
Presumptive anti- 14,344 (23.2)
273 (0.1)
relapse therapy
MTF = military treatment facility.

OR (95% CI)

0.58 (0.56–0.60)

dominant experience across the military as both a medical
provider and as a traveler/deployer would be with deployments to Afghanistan, where DX is the standard. A shift in
chemoprophylaxis choice between service member and
beneﬁciary is not seen (Supplemental Figure 5C) among nontravel medicine specialty types, inferring that these military
providers base their practice on shared experience that comes
from deployment and knowledge of FHP policies into contexts
for which they were not designed. This would also explain the
disproportionate prescribing of PART by military providers in
general, but particularly for nonspecialists to beneﬁciaries. A
question of interest is whether broader experience with AP
during operations in Africa, combined with decreasing forces
in Afghanistan, will eventually lead to further increased uptake
of AP across all military practice settings in the future. The
impending impact of tafenoquine implementation will need
assessment. Of special note, although these results suggest a
more nuanced approach to clinical decision making by travel
medicine specialists seeing both service member and beneﬁciary populations, their relative impact on the overall provision of care is comparably small, accounting for less than
1% of all chemoprophylaxis prescriptions.
Force health protection policy–driven care for service
members provides a public health–oriented, evidence-based
approach to risk communication with the deployer/traveler
and for clinical decision-making of prevention interventions.23
As shown in this study, there are a number of high-volume
clinical settings not staffed by travel medicine specialists.
Even if one considers the delivery of care provided at highvolume mobilization sites to be “specialized,” the practitioners
involved would not necessarily develop the depth and breadth
of experience one might expect of someone with the intensive
graduate medical education travel medicine experience of
military Preventive Medicine and Infectious Disease programs, nor the Masters of Tropical Medicine & Hygiene degree
and other tropical and travel medicine courses at the Uniformed Services University or similar civilian programs.24,25
TABLE 5
Comparison of military treatment facility nonspecialists vs. civilian
facility prescriptions
Medication

0.23 (0.22–0.24)
2.76 (2.70–2.83)
0.40 (0.38–0.42)
1.92 (1.54–2.40)
–
45.7 (40.60–51.63)

Atovaquone–proguanil
Chloroquine
Doxycycline
Meﬂoquine
Primaquine
Presumptive antirelapse therapy

Service members,
OR (95% CI)

0.27 (0.26–0.28)
0.05 (0.04–0.06)
5.62 (5.41–5.83)
0.12 (0.11–0.13)
0.50 (0.36–0.72)
7.42 (7.00–7.88)

Beneﬁciaries,
OR (95% CI)

0.36 (0.35–0.38)
0.21 (0.19–0.22)
4.12 (4.01–4.24)
0.40 (0.38–0.43)
1.77 (1.38–2.26)
53.4 (47.32–60.28)
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Nor would experience at high-volume FHP policy–driven sites
deploying large numbers of troops for a very speciﬁc mission
proﬁle, necessarily translate well for varied mission settings,
nor mirror mastery of the depth and breadth of knowledge
required of American Society of Travel Medicine & Hygiene’s
Certiﬁcate of Knowledge in Clinical Tropical Medicine and
Travelers’ Health (the CTropMed®) or the International Society
of Travel Medicine Certiﬁcate program.26,27
Force health protection policy is designed by experts for
both the itinerary, risk tolerance, and baseline health proﬁle of
active duty service members, but they are not designed for the
broader population of beneﬁciaries. The analysis described
here is not designed to assess whether the observed variation
in practice represents “error” versus a wide range of acceptable practice patterns. Yet, the lack of tailoring to patient
context suggests that specialists may provide higher quality
care. Furthermore, one must consider whether the variation in
antimalarial prescription is the proverbial “ears of the hippopotamus” representing the risk of unseen variation and disparities in other aspects of travel medicine prevention
practices.28 Whether this equates to increased risk of harm to
a patient is an important question that requires further study.
Within MTFs, 50 percent of the total number of antimalarial
prescriptions are written by medical providers who wrote
fewer than three chemoprophylaxis prescriptions during the
5-year study period. Concern over the level of experience and
applied practice in travel medicine must be taken seriously.
Knowledge, attitude, and practice surveys of deployed military medical providers show as many as two-thirds made errors in prescription and management of travelers diarrhea.29,30
Furthermore, studies among civilian primary care practitioners
consistently show gaps in travel self-efﬁcacy, knowledge, and
reported practice particularly associated with low practice
volume.31,32 Rather than focusing on sustaining a high level of
training-based proﬁciency, beyond knowledge of FHP, for a large
(tens of thousands) number of medical providers across hundreds of medical facilities, it seems appropriate to optimize the
access and use of decision support systems (e.g., Travax and the
CDC’s Travelers’ Health resources). Given the facility-level data
described in this report, from a health system policy perspective,
it is equally or more important to ensure access to specialists in
travel medicine at high-volume sites both for direct patient care
and to serve as subject matter expert resources.
This study design has several limitations. First, this study
did not include detailed medical record review to conﬁrm the
purpose of each prescription, reason for travel, or total duration. Because DX is not solely an antimalarial, we anticipate
some misclassiﬁcation bias, although it is likely nondifferential. Second, it is possible we may not be capturing
all prescriptions by deployed units, if not captured by the
electronic medical record. Third, the determination of purpose
for PQ use was abstracted based on the number dispensed,
so it is possible that doxycycline for trips lasting less than
1 week was not captured, and primary prophylaxis prescriptions of primaquine for trips requiring an amount equal to
PART regimens were misclassiﬁed. Finally, we were unable to
determine the medical specialty of civilian facility prescribers
with the data available, so unable to conduct the same degree
of analyses as those within the MTFs for whom those data are
available. Some handwritten prescriptions originating in a civilian facility may have been ﬁlled at a military pharmacy, or
vice versa. The MDR contains multiple separate data ﬁles. The
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prescription data ﬁle does include a facility ID code for where
the prescription was dispensed and prescribing provider demographics. Although prescribing facility information is
readily available for prescriptions originating in and dispensed
at military pharmacies (as discussed), these data ate not
captured for “purchased care” prescriptions written outside of
military facilities and ﬁlled at civilian pharmacies. Linking civilian prescriptions back to more detailed encounter data is
theoretically possible but technically fraught because of the
lack of a common linking variable between the two ﬁles and
the lack of consistent ICD coding practice for travel medicine
services. More detailed analysis of civilian provider demographics (e.g., medical specialty) would enhance the
generalizability of this analysis. Unfortunately, this approach
would still not allow for a practice volume–based comparison
because a given civilian provider may perform at a high rate of
travel medicine encounters in general but only rarely see Military
Health System patients. Reﬁning this analytic approach will be
undertaken in future analyses within the KAPOS line of effort.
KAPOS has several strengths. The large sample size provided adequate power for detecting small differences in a
variety of subset analyses. Inclusion of prescriptions originating from civilian facilities and of beneﬁciaries enhances
our generalizability to the larger U.S. population. In general,
longitudinal data on malaria chemoprophylaxis prescribing
patterns is limited. Although longitudinal studies have
recorded prescribing patterns in specialty travel clinics and
participating primary care clinics through TravEpiNet, that
study may not reﬂect broader national practice patterns,
particularly in non-travel medicine specialty clinics.33
KAPOS provides an aggregate look at civilian prescribing
patterns, which includes a variety of clinic settings such as
primary care and specialty clinics. We were also able to show
detailed analysis of primary care patterns separately, albeit
those originating from MTFs.
It is clear that as the Department of Defense moves toward a
learning healthcare system model, data provided by platform
systems such as KAPOS, augmented with methods to determine appropriateness (or non-appropriateness) of deployment and travel health practices and combined with direct
surveys to post-travelers/deployers, will inform and accelerate implementation of higher quality care to our service
members and beneﬁciaries. Models of such a system have
been shown to be successful with the example of the Joint
Trauma System—no such system exists for non-trauma infectious disease deployment health quality practice management, but is sorely needed.34
CONCLUSION
Malaria prophylaxis patterns may vary by practice setting,
beneﬁciary status, and medical specialty. Although both civilian and military facilities prescribe an increasing proportion
of AP, DX remains the most prevalent antimalarial at military
facility–based practice. Civilian providers dispense higher
rates of MQ than their military counterparts. Force health
protection policy plays an important role in standardizing and
improving the quality of care for deployed service members.
Among primary care specialties, these practices appear to
carry over, but this may not be the perfect solution outside of
the large-scale deployment context. If in fact the practice
variations described here do translate into disparate health
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outcomes, then solutions that broaden access to and uptake
of the knowledge products or specialty care are required.
Given the diffuse nature of travel medicine services represented by the high number of low-volume malaria chemoprophylaxis prescribers, facility-based solutions may be the
key. Additional studies within the U.S. military context looking
at the relationship between provider specialty and practice
volume on self-efﬁcacy, quality of care, and patient outcomes
in this context are needed.
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